Sign In
Buy CTS
CTS Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $0.520 |
| EPS actual | $0.620 |
| EPS Surprise | 19.23% |
| Revenue estimate | 136.827M |
| Revenue actual | 139.2M |
| Revenue Surprise | 1.73% |
| Release date | Feb 10, 2026 |
| EPS estimate | $0.600 |
| EPS actual | $0.620 |
| EPS Surprise | 3.33% |
| Revenue estimate | 135.856M |
| Revenue actual | 137.271M |
| Revenue Surprise | 1.04% |
| Release date | Oct 28, 2025 |
| EPS estimate | $0.610 |
| EPS actual | $0.600 |
| EPS Surprise | -1.64% |
| Revenue estimate | 135.856M |
| Revenue actual | 142.97M |
| Revenue Surprise | 5.24% |
| Release date | Jul 24, 2025 |
| EPS estimate | $0.550 |
| EPS actual | $0.570 |
| EPS Surprise | 3.64% |
| Revenue estimate | 136.397M |
| Revenue actual | 135.309M |
| Revenue Surprise | -0.798% |
Last 4 Quarters for CTS
Below you can see how CTS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 24, 2025 |
| Price on release | $42.00 |
| EPS estimate | $0.550 |
| EPS actual | $0.570 |
| EPS surprise | 3.64% |
| Date | Price |
|---|---|
| Jul 18, 2025 | $41.02 |
| Jul 21, 2025 | $40.67 |
| Jul 22, 2025 | $40.71 |
| Jul 23, 2025 | $40.44 |
| Jul 24, 2025 | $42.00 |
| Jul 25, 2025 | $41.43 |
| Jul 28, 2025 | $41.53 |
| Jul 29, 2025 | $41.25 |
| Jul 30, 2025 | $40.47 |
| 4 days before | 2.39% |
| 4 days after | -3.64% |
| On release day | -1.36% |
| Change in period | -1.34% |
| Release date | Oct 28, 2025 |
| Price on release | $40.51 |
| EPS estimate | $0.610 |
| EPS actual | $0.600 |
| EPS surprise | -1.64% |
| Date | Price |
|---|---|
| Oct 22, 2025 | $40.98 |
| Oct 23, 2025 | $42.16 |
| Oct 24, 2025 | $42.16 |
| Oct 27, 2025 | $42.44 |
| Oct 28, 2025 | $40.51 |
| Oct 29, 2025 | $41.13 |
| Oct 30, 2025 | $40.76 |
| Oct 31, 2025 | $41.51 |
| Nov 03, 2025 | $41.64 |
| 4 days before | -1.15% |
| 4 days after | 2.79% |
| On release day | 1.53% |
| Change in period | 1.61% |
| Release date | Feb 10, 2026 |
| Price on release | $57.29 |
| EPS estimate | $0.600 |
| EPS actual | $0.620 |
| EPS surprise | 3.33% |
| Date | Price |
|---|---|
| Feb 04, 2026 | $53.83 |
| Feb 05, 2026 | $54.19 |
| Feb 06, 2026 | $55.78 |
| Feb 09, 2026 | $55.58 |
| Feb 10, 2026 | $57.29 |
| Feb 11, 2026 | $57.15 |
| Feb 12, 2026 | $56.92 |
| Feb 13, 2026 | $57.46 |
| Feb 17, 2026 | $56.00 |
| 4 days before | 6.43% |
| 4 days after | -2.25% |
| On release day | -0.244% |
| Change in period | 4.03% |
| Release date | Apr 29, 2026 |
| Price on release | $54.43 |
| EPS estimate | $0.520 |
| EPS actual | $0.620 |
| EPS surprise | 19.23% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $55.53 |
| Apr 24, 2026 | $56.77 |
| Apr 27, 2026 | $55.98 |
| Apr 28, 2026 | $54.27 |
| Apr 29, 2026 | $54.43 |
| Apr 30, 2026 | $57.10 |
| May 01, 2026 | $57.00 |
| May 04, 2026 | $56.53 |
| May 05, 2026 | $58.07 |
| 4 days before | -1.98% |
| 4 days after | 6.69% |
| On release day | 4.91% |
| Change in period | 4.57% |
CTS Earnings Call Transcript Summary of Q1 2026
CTS reported a solid Q1 2026: sales of $139M (+11% YoY), with diversified end markets up 18% and transportation up 3%. Book-to-bill was 1.1 and total booked business was ~$1.1B. Key drivers were strong bookings and momentum in industrial and medical markets, multiple new customer wins (including defense and transportation), and operational execution that expanded gross margin by 250 bps to 39.5% (adjusted). Adjusted diluted EPS was $0.62 (vs. $0.44 prior year). Cash generation remained healthy ($17M operating cash flow; $91M cash; $63M borrowings), and the company returned $10M to shareholders and repurchased $9M of stock in Q1. Management reiterated a diversification strategy (Evolution 2030), ongoing capacity expansion in medical (aesthetics/therapeutics), expectation that defense funding and bookings should pick up in H2 2026, and cautioned on potential headwinds from geopolitical uncertainty, commodity and resin inflation, and Section 232 tariff changes. Assuming current conditions, full-year 2026 guidance was narrowed to $560M–$580M revenue and $2.35–$2.45 adjusted diluted EPS. Management remains active on M&A but prioritizes organic investments, margin protection, and returning cash to shareholders.
